Characteristics of inv(16) AML patients
| Patient no. . | Relevant FABcytogenetic classificationaberrations . | Percentage of blasts* . | Inv(16) PCR product (bp) . | Treatment† . | |
|---|---|---|---|---|---|
| 1 | M4Eo | inv(16) | 85 | 420 | Ara-C, DNR, VCR |
| 2‡ | M1 | N | 95 | — | Ara-C, Ida |
| 3 | M4Eo | inv(16) | 90 | 420 | Ara-C, Ida, Amsa |
| 4 | M4Eo | inv(16) | 80 | 420 | Ara-C, Ida, Amsa |
| 5 | M4Eo | inv(16) | 90 | 1400 | Ara-C, Ida, Amsa |
| 6 | M4Eo | inv(16) | 80 | 420 | Ara-C, DNR, Amsa |
| 7 | M4Eo | inv(16) | 90 | 420 | Ara-C, DNR, Amsa |
| 8 | M4Eo | inv(16) | 95 | 420 | Ara-C, Ida** |
| 9 | M2 | inv(16) | 85 | 1200 | Ara-C, Ida, Amsa |
| 10 | M4Eo | inv(16) | 95 | — | Ara-C, DNR |
| 11 | M4Eo | der(11)t(11;16), der(16)inv(16)t(11;16) | 95 | 420 | Ara-C, Ida, Amsa |
| Patient no. . | Relevant FABcytogenetic classificationaberrations . | Percentage of blasts* . | Inv(16) PCR product (bp) . | Treatment† . | |
|---|---|---|---|---|---|
| 1 | M4Eo | inv(16) | 85 | 420 | Ara-C, DNR, VCR |
| 2‡ | M1 | N | 95 | — | Ara-C, Ida |
| 3 | M4Eo | inv(16) | 90 | 420 | Ara-C, Ida, Amsa |
| 4 | M4Eo | inv(16) | 80 | 420 | Ara-C, Ida, Amsa |
| 5 | M4Eo | inv(16) | 90 | 1400 | Ara-C, Ida, Amsa |
| 6 | M4Eo | inv(16) | 80 | 420 | Ara-C, DNR, Amsa |
| 7 | M4Eo | inv(16) | 90 | 420 | Ara-C, DNR, Amsa |
| 8 | M4Eo | inv(16) | 95 | 420 | Ara-C, Ida** |
| 9 | M2 | inv(16) | 85 | 1200 | Ara-C, Ida, Amsa |
| 10 | M4Eo | inv(16) | 95 | — | Ara-C, DNR |
| 11 | M4Eo | der(11)t(11;16), der(16)inv(16)t(11;16) | 95 | 420 | Ara-C, Ida, Amsa |
AML indicates acute myeloid leukemia; FAB, French-American-British; PCR, polymerase chain reaction; N, normal; Ara-C, cytosine arabinoside; DNR, daunorubicin; VCR, vincristine; Ida, idarubicin; Amsa, amsacrine.
Percentage of blasts determined by May-Grünwald Giemsa staining, except for patient 4, where it was determined according to the percentage of CD33+ cells.
Patient 1 was treated according to the protocol of the European Organization for the Research and Treatment of Cancer; other patients were treated according to the protocol of the Dutch-Belgian Hemato-Oncology Cooperative Group (Hovon).
This patient sample showed no MRP1 protein expression and a low MRP activity in a previous study.12